Immunome (IMNM) EBIT Growth (3y) (2022 - 2026)

Immunome (IMNM) EBIT Growth (3y) (2022 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBIT Growth (3y) (Qtr)
1 Oculis Holding AG 67,072.09 Bn 67,072.09 Bn - -
2 Nanobiotix 1,894.61 Bn 1,894.55 Bn - -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn - -
4 BeOne Medicines 471.64 Bn 466.85 Bn 1.35 Bn 38.78%
5 Vertex Pharmaceuticals 121.72 Bn 114.47 Bn 2.59 Bn 13.47%
6 Regeneron Pharmaceuticals 68.28 Bn 59.52 Bn 3.31 Bn -12.10%
7 Belite Bio 61.40 Bn 61.40 Bn - -
8 Argenx Se 56.94 Bn 56.94 Bn 1.18 Bn 79.65%
9 Revolution Medicines 37.37 Bn 37.37 Bn - -
10 Immunome 2.51 Bn 1.93 Bn - -136.75%

Historic Data

Download Data
DateValue
Mar 31, 2026 -136.75%
Dec 31, 2025 -110.72%
Sep 30, 2025 -91.72%
Jun 30, 2025 -73.33%
Mar 31, 2025 -56.46%
Dec 31, 2024 -119.51%
Sep 30, 2024 -87.02%
Jun 30, 2024 -91.02%
Mar 31, 2024 -223.80%
Dec 31, 2023 -185.37%
Sep 30, 2023 -18.02%
Jun 30, 2023 -28.59%
Mar 31, 2023 -18.97%
Dec 31, 2022 -39.18%
Sep 30, 2022 -46.40%